Skip to main content

EXOZYMES INC.

For the period ended Jun 30, 2026. Filed Aug 13, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2026 · Filed Aug 13, 2026

EXOZ$4.40+7.1%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits

Cover page

Show cover page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED JUNE 30,2026

OR

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number:001-42204

EXOZYMES INC.

(Exact name of registrant as specified in its charter)

Nevada83-4550057
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
750 Royal Oaks Drive, Suite 106 Monrovia, CA 9101691016
(Address of principal executive offices)(Zip code)

(626) 415-1488

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $.000001EXOZNasdaq Capital Markets

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the last 90 days.YES ☒ NO ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).YES ☒ NO ☐

Indicate by check mark whether the registrant is a large, accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large, accelerated filer,” “accelerated filer,” “non-accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer☐Accelerated Filer☐
Non-accelerated Filer☐Smaller Reporting Company☒
Emerging Growth Company☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).YES ☐ NO☒

As of August 13, 2026, the number of outstanding shares of Common Stock was 9,281,359.

TABLE OF CONTENTS

Page Number
PART IFINANCIAL INFORMATION3
Item 1 - Condensed Unaudited Consolidated Financial Statements3
Condensed Unaudited Consolidated Balance Sheets – June 30, 2026, and December 31, 20253
Condensed Unaudited Consolidated Statements of Operations – Three months and Six months ended June 30, 2026, and 20254
Condensed Unaudited Consolidated Statements of Changes in Equity – Three months and Six months ended June 30, 2026, and 20255
Condensed Unaudited Consolidated Statements of Cash Flows – Six months ended June 30, 2026, and 20256
Notes to Condensed Unaudited Consolidated Financial Statements7
Item 2Management’s Discussion and Analysis of Financial Conditions and Results of Operations22
Item 3Quantitative and Qualitative Disclosures About Market Risk28
Item 4Controls and Procedures28
PART IIOTHER INFORMATION30
Item 1Legal Proceedings30
Item 1ARisk Factors30
Item 2Unregistered Sales of Equity Securities and Use of Proceeds31
Item 3Defaults upon Senior Securities31
Item 4Mine Safety Disclosures31
Item 5Other Information31
Item 6Exhibits31

In this Quarterly Report, unless otherwise indicated, the “Company”, “eXoZymes,” “we”, “us” or “our” refer to eXoZymes Inc. and, where appropriate, together with its wholly owned subsidiaries.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.